WallStSmart

Cigna Corp (CI)vsVuzix Corp Cmn Stk (VUZI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cigna Corp generates 4424509% more annual revenue ($277.89B vs $6.28M). CI leads profitability with a 2.3% profit margin vs 0.0%. CI earns a higher WallStSmart Score of 68/100 (B-).

CI

Strong Buy

68

out of 100

Grade: B-

Growth: 6.7Profit: 6.0Value: 9.3Quality: 4.8
Piotroski: 2/9

VUZI

Avoid

26

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: -4.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CIUndervalued (+79.2%)

Margin of Safety

+79.2%

Fair Value

$1363.84

Current Price

$288.06

$1075.78 discount

UndervaluedFair: $1363.84Overvalued
VUZIUndervalued (+43.1%)

Margin of Safety

+43.1%

Fair Value

$4.34

Current Price

$3.11

$1.23 discount

UndervaluedFair: $4.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CI5 strengths · Avg: 8.6/10
P/E RatioValuation
11.8x10/10

Attractively priced relative to earnings

Market CapQuality
$75.14B9/10

Large-cap with strong market position

PEG RatioValuation
0.838/10

Growing faster than its price suggests

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
29.1%8/10

Earnings expanding 29.1% YoY

VUZI2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
76.3%10/10

Revenue surging 76.3% year-over-year

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

CI3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

Profit MarginProfitability
2.3%3/10

2.3% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

VUZI4 concerns · Avg: 3.5/10
Price/BookValuation
10.4x4/10

Trading at 10.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$239.50M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : CI

The strongest argument for CI centers on P/E Ratio, Market Cap, PEG Ratio. PEG of 0.83 suggests the stock is reasonably priced for its growth.

Bull Case : VUZI

The strongest argument for VUZI centers on Revenue Growth, Debt/Equity. Revenue growth of 76.3% demonstrates continued momentum.

Bear Case : CI

The primary concerns for CI are Revenue Growth, Profit Margin, Piotroski F-Score. Thin 2.3% margins leave little buffer for downturns.

Bear Case : VUZI

The primary concerns for VUZI are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

CI profiles as a value stock while VUZI is a hypergrowth play — different risk/reward profiles.

VUZI carries more volatility with a beta of 1.52 — expect wider price swings.

VUZI is growing revenue faster at 76.3% — sustainability is the question.

CI generates stronger free cash flow (864M), providing more financial flexibility.

Bottom Line

CI scores higher overall (68/100 vs 26/100). VUZI offers better value entry with a 43.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cigna Corp

HEALTHCARE · HEALTHCARE PLANS · USA

Cigna is an American multinational managed healthcare and insurance company based in Bloomfield, Connecticut. Its insurance subsidiaries are major providers of medical, dental, disability, life and accident insurance and related products and services, the majority of which are offered through employers and other groups (e.g. governmental and non-governmental organizations, unions and associations).

Visit Website →

Vuzix Corp Cmn Stk

TECHNOLOGY · CONSUMER ELECTRONICS · USA

Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.

Want to dig deeper into these stocks?